The Hypothesized Role of Dopamine in Bipolar I Disorder
Dopamine is a neurotransmitter thought to play a key role in mood regulation. Test your understanding of how dopamine signaling may be associated with symptoms of bipolar I disorder (BP-1) and ways it can potentially be modulated in the pharmacologic management of BP-1.
References
Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. Cambridge University Press; 2013:89-96.
- Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi:10.1155/2014/656370
- Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract. 1992;17(11):56-67. doi:10.1097/00006205-199211000-00018
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text revision. American Psychiatric Association Publishing; 2022.
- Nichols CD, Amara SG, Sibley R. 5-hydroxytryptamine (serotonin) and dopamine. In: Brunton LL, Knollmann BC, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill Education; 2023. Accessed February 27, 2025. https://accessmedicine-mhmedical-com.jerome.stjohns.edu/content.aspx?bookid=3191§ionid=266700287
- Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366. doi:10.1146/annurev.med.60.042307.110802
- Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666-679. doi:10.1038/mp.2017.16
- Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20(6):661-70. doi:10.1038/mp.2015.4
- Edinoff AN, Akuly HA, Hanna TA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387-401. doi:10.3390/neurolint13030038
- Rosenberg G. Cell Mol Life Sci. 2007;64(16):2090-103. doi:10.1007/s00018-007-7079-x
- Weston-Green K. Antipsychotic drug development: from historical evidence to fresh perspectives. Front Psychiatry. 2022;13:903156. doi:10.3389/fpsyt.2022.903156
- Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251-267. doi:10.2165/00023210-200418040-00005
This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
ABBV-US-01992-MC, V1.0
Approved 05/2025
AbbVie Medical Affairs